Recent evidence has shifted the paradigm of white adipose tissue from simple energy storage to the body's major endocrine and paracrine organ synthesizing and releasing multiple signaling proteins, collectively termed adipokines. White adipose tissue is distributed in two large depots (subcutaneous and visceral) and many small depots associated with the heart, blood vessels, lymph nodes, ovaries, mammary glands, prostate gland, pancreas. Even in a lean person, adipose tissue represents about 15-20 % of body weight, including external (subcutaneous and visceral) and internal (organ-associated) adipose tissue, the latter being even more important than the former; however the internal fat distribution was beyond the scope of the present study. nonalcoholic fatty liver disease (naFlD) is a term used to describe the accumulation of fat in the liver of people in the absence of alcohol consumption or consumption of less than 20g/day. It is a progressive, low-grade inflammatory disease related to obesity and metabolic syndrome. naFlD represent a spectrum of disorders ranging from fat accumulation (steatosis) to nonalcoholic steatohepatitis (nash) that can progress to fibrosis and cirrhosis. The aim of the present study was to evaluate the clinic and metabolic parameters in patients with type 2 diabetes and naFlD depending on gender and bmI and to assess relation of adipose tissue distribution with insulin resistance. Total of 118 patients (mean age 55.93 years; male, 46, female, 72) with type 2 diabetes evaluated in an outpatient diabetes clinic were diagnosed with naFlD by ultrasonography and were assessed by weight, body mass index (bmI), waist circumference, fasting plasma glucose, hbalc, and fasting insulin level. We calculated the hOma-IR index [Fpg (mmol/l) x FI (μu/ml)]:22.5. body adipose percentage and trunk adipose content were measured using bioelectrical impedance analysis (TanITa bc-418). Overall, the present results suggest that insulin resistance may be considered a pathogenic link between T2Dm and naFlD, also at the level of adipose tissue distribution. Evaluating the distribution of internal, organ-associated adipose tissue remains a challenge for future studies in patients with T2Dm and naFlD. Adipobiology 2012; 4: 97-101 
introduction
Over the past 20-25 years, obesity and related diseases are among the major physical, social and economic burdens worldwide (1) . The World Health Organization has predicted a "globesity epidemic" with more than one billion adults being overweight (BMI over 25 kg/m 2 ) and at least 400 million of these being clinically obese (BMI over 30 kg/m 2 ). Arguably, we have learned more about the presence, distribution and function of adipose tissue. Also about the molecular control of food intake and energy homeostasis, particularly, the role played by adipose tissue in the pathogenesis of cardiometabolic, malignant, neurodegenerative and liver (2, 3) diseases.
Even in a lean person, adipose tissue represents about 15-20 % of body weight, including external (subcutaneous and visceral) and internal (organ-associated) adipose tissue, the latter being even more important than the former (4). Even along the same organ, for example, the aorta, the composition of the adipose tissue surrounding the thoracic and abdominal parts of the aorta differs; the more abdominal part is surrounded by white adipose tissue, which is subject to obesity-related inflammation, whereas the thoracic part is surrounded by brown adipose tissue (Nicholas Hatch, 2012, Research Gate, comment).
In humans, adipose tissue (hereafter to be considered white adipose tissue) is partitioned into two large depots (subcutaneous and visceral) and many small depots associated with heart, blood vessels, major lymph nodes, pancreas, prostate gland, mammary glands, ovaries, thymus. Noteworthy, upper-body adipose distribution is associated with complications of obesity while lower-body adipose distribution is protective though the mechanisms that govern regional adipose accumulation (5, also see these latter authors in this issue of Adipobiology).
Nonalcoholic fatty liver disease (NAFLD) is a term used to describe the accumulation of fat in the liver of people in the absence of alcohol consumption or consumption of less than 20g/ day. NAFLD represent a spectrum of disorders ranging from steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. It is a progressive, low-grade inflammatory disease characterized by fatty infiltration and association with obesity and metabolic syndrome. Patients with NAFLD may even respond to therapy (and weight loss) originally developed for other insulinresistant states. Many studies have demonstrated a link between NAFLD and insulin sensitivity, but the association with obesity and type 2 diabetes mellitus (T2DM) is a continuing subject of debate because not all obese individuals with diabetes present NAFLD, and not all patients with NAFLD are overweight or insulin resistant. Increasing age, obesity and diabetes are considered independent predictors for the progression to nonalcoholic steatohepatitis (NASH) and fibrosis (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Many epidemiological studies have established a strong correlation between body mass index (BMI) and the presence of fatty liver diagnosed by ultrasonography. Of patients diagnosed with NAFLD, 30-100% are obese (9) , and 76% of obese patients have NAFLD, compared to 16% of normal weight individuals (10) . In overweight and obese patients with abnormal liver test results, liver biopsies revealed septal fibrosis and cirrhosis in 30% and 10% of cases, respectively. In order to evaluate the risk of developing fibrosis, a score was calculated using the following combined values: BMI, age, alanine aminotransferase (ALT) and triglyceride levels (11) . A predictive value for progression to fibrosis was assigned to a quantitative index of insulin resistance (Homeostasis Model Assessment for Insulin Resistance -HOMA-IR) in severely obese patients (14) .
Studies that used liver histology to identify the presence of NAFLD have shown that some patients with NAFLD have normal weight and normal waist circumference. Using waist circumference as a surrogate marker of visceral adiposity, 431 patients with NAFLD diagnosed via liver biopsy were analyzed. Increasing visceral obesity was correlated with older age, a higher prevalence among females, altered glucose metabolism, hypertension and metabolic syndrome. The progression to NASH and the presence of fibrosis were not associated with visceral adiposity. Higher ALT levels and HOMA-IR more than 4 were associated with NASH independent of the presence of visceral adiposity (12) .
The aim of the present study was to evaluate the clinic and metabolic parameters in patients with T2DM and NAFLD depending on gender and BMI and to assess relation of adipose tissue distribution with insulin resistance.
patients and methods
A total of 118 patients (mean age 55.93 years; M/W, 46/72) with T2DM evaluated in an outpatient diabetes clinic were diagnosed with NAFLD by ultrasonography and were assessed by height, weight, body mass index (BMI, kg/m 2 ), waist circumference (WC, cm), fasting plasma glucose (FPG, mg/dl), HbAlc (%), and fasting insulin (FI, μU/ml). We calculated the HOMA-IR index [FPG (mmol/l) x FI (μU/ml)]:22.5. Body fat percentage and trunk fat content were measured using bioelectrical impedance analysis (TANITA BC-418). Exclusion criteria: positive serologic markers for viral hepatitis and alcohol consumption > 20g/day. The statistical analysis program used was SPSS 15.0, with a statistical significance of p≤0.05*, p<0.001**.
results
We observed a high prevalence of females versus males: 72 (61.01%) versus 46 (38.98%). According to BMI values, we defined two groups: group 1 consisted of 30 patients with a BMI > 25 kg/m 2 and < 30 kg/m 2 , and group 2 included 88 patients with a BMI ≥30 kg/m 2 . Of the patients studied, 25.42% were overweight and 74.57% were obese. Clinical and biochemical variables of studied patients organized by gender distribution and BMI values are listed in Table 1 .
Anthropometric and metabolic parameters were analyzed between overweight and obese patients for women and for men ( Table 2 ).
In the female group, fasting insulin (FI) levels and HOMA- 
